Scholar Rock raises $36M in series B

Scholar Rock LLC (Cambridge, Mass.) raised $36 million in a series B round led by new investor Fidelity. New investor Cormorant Asset Management joined existing investors Polaris Partners, Timothy Springer, Arch Venture Partners, EcoR1 Capital and The Kraft Group.

This half, the company expects to submit an IND for lead candidate SRK-015, an inhibitor of latent myostatin ( MSTN; GDF8) activation, to treat primary myopathies. It expects to have clinical data in 2017. CEO Nagesh Mahanthappa declined to disclose a specific indication for SRK-105 or a design for the Phase I study (see BioCentury Extra, Sept. 23, 2015). ...